We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
Digoxin
From WikEM
Contents
General
- Type: Cardiac glycoside; CHF medications
- Dosage Forms: PO, IV, IM
- Common Trade Names: Digitek, Digox, Lanoxin (US)
Adult Dosing
- Loading dose = 0.25mg IV q2hr until effect (max total = 1.5mg)
- in acute atrial fibrillation with RVR with heart failure = 0.5mg IV, then 0.25mg IV q4hr until effect or max 1.5mg
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Indications
- RVR control in a-fib/flutter, PSVT
Contraindications
- Allergy to class/drug
- WPW
- Increases conduction velocity in atrial tissue
Adverse Reactions
- GI: nausea and vomiting, diarrhea, abdominal pain
- CV: Bradycardia, SA/AV block, ventr arrhythmias
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Kinetics
- Onset of action = 1.5-4hr (IV)
Mechanism of Action
- Inhibits Na+/K+ ATPase in the myocardium[1]
- Causes increase in intracellular sodium levels
- Results in reversal of sodium-calcium exchanger
- Normally imports three extracellular sodium ions into the cardiac myocyte in exchange for one intracellular calcium being exported
- Sodium accumulates intracellularly and is exchanged for Calcium.
- Causes an increase in the intracellular calcium concentration increasing contractility
- Also a lengthening of phase 4 and phase 0 of the cardiac action potential which ultimately decreases heart rate
- Summary
- Inhibits NaK pump
- Positive inotropy
- Negative chronotropy/dromotropy
- Indirect vagal stimulator
- Inhibits NaK pump
Comments
See Also
References
- ↑ Gheorghiade M. et al. Digoxin in the Management of Cardiovascular Disorders. Circulation. 2004; 109: 2959-2964